Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.74 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗

October 03, 2022

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.

Via Benzinga

Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise ↗

September 14, 2022

Via Benzinga

Why Is Akero Therapeutics (AKRO) Stock Up 120% Today? ↗

September 13, 2022

AKRO stock is soaring 120% and is one of today's top-trending tickers. Akero released positive data on its drug candidate.

Via InvestorPlace

Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study ↗

September 13, 2022

Via Benzinga

Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session ↗

September 30, 2022

Gainers

Via Benzinga

Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday ↗

September 30, 2022

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Analysts Are Bullish On 89bio's NASH Data Slated For Early Next Year ↗

August 18, 2022

Via Benzinga

This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations ↗

July 11, 2022

Via Benzinga

Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 14, 2022

Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 ↗

September 14, 2022

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...

Via Benzinga

Evercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck ↗

September 14, 2022

Berenberg raised the price target for Merck & Co., Inc. (NYSE: MRK) from $95 to $100. Merck shares rose 0.7% to $86.22 in pre-market trading.

Via Benzinga

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary ↗

September 13, 2022

Via Benzinga

Dow Drops More Than 1,000 Points, Akero Therapeutics Shares Spike Higher ↗

September 13, 2022

U.S. stocks traded sharply lower toward the end of trading, following the release of inflation data for August.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 13, 2022

Via Benzinga

Akero Therapeutics (NASDAQ: AKRO) Squeezes Shorts After Stronger-then-Expected Results from Phase 2b HARMONY Study of EFX

September 13, 2022

Akero Therapeutics, Inc. (NASDAQ: AKRO) is engaged as a clinical-stage biotechnology company that is focused on the research and development

Via Spotlight Growth

Looking Into Akero Therapeutics's Recent Short Interest ↗

September 13, 2022

Akero Therapeutics's (NASDAQ:AKRO) short percent of float has risen 6.59% since its last report. The company recently reported that it has 6.18 million shares sold short,...

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

Nasdaq Tumbles 500 Points, Crude Oil Down Over 1% ↗

September 13, 2022

U.S. stocks extended losses midway through trading, following the release of inflation data for August

Via Benzinga

Akero Therapeutics Inc. (NASDAQ: AKRO) Sets New 52-Week High in Tuesday Morning Session

September 13, 2022

Via Investor Brand Network

Planet Labs, Core & Main And Some Other Big Stocks Moving Higher On Tuesday ↗

September 13, 2022

U.S. stocks traded lower, with the Dow Jones tumbling more than 800 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

US Stocks Open Lower After Inflation Report, Dow Dips 700 Points ↗

September 13, 2022

U.S. stocks traded sharply lower this morning, following the release of inflation data for August

Via Benzinga

What Is Going on With NeuroBo (NRBO) Stock Today? ↗

September 13, 2022

NeuroBo Pharmaceuticals (NRBO) stock is rocketing higher on Tuesday after the company underwent a reverse stock split this morning.

Via InvestorPlace

Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment ↗

September 13, 2022

The company's NASH drug outperformed a placebo at every turn over 24 weeks.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 13, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 13, 2022

Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!

Via InvestorPlace

Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday ↗

September 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in...

Via Benzinga

Akero Lead Candidate Improves Fibrosis In Cirrhotic NASH Patients ↗

August 24, 2022

Akero Therapeutics Inc's (NASDAQ: AKRO) results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis (NASH) have been published in JHEP Reports.

Via Benzinga

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit? ↗

July 05, 2022

The FDA's advisors recently backed Pfizer's Covid shot for young children.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.